(Boursier.com) — Implanet announces annual revenue for 2022
of 8 ME, up 31% with a record level of sales of JAZZ solutions in units (+31%) and a continuation of the good export sales momentum recorded in the first three quarters of the 2022 financial year.
Ludovic Lastennet, Chief Executive Officer of the group, declared: “We are ending 2022 with a good performance internationally. Despite the slowdown in activity that we are currently experiencing on the French market, we have achieved a solid financial year, marked by continuous growth. This performance demonstrates the relevance of the various partnerships that we have been able to deploy internationally and comforts us with regard to the strategic axes to which we have been committed for more than two years. The year 2023 should be marked by the implementation of our partnership with Sanyou Medical. The procedures for registering our JAZZ platform in China are underway and we hope to be able to register the first orders for the ultrasonic surgical scalpel from SMTP, a subsidiary of Sanyou Medical, in the first quarter 2023. All of these elements confirm our objectives of achieving financial equilibrium in the medium term and becoming a n a key player in the treatment of spinal pathologies, in France and internationally.”
Next financial press release: 2022 annual results, March 7, 2023 after market close.
©2023 Boursier.com